1,3-二甲基丁衍生物具有高强度作为人类氨酸受体的对手A2B
Kenneth A Jacobson1, Ad P IJzerman2, Joel Linden3
1Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Drug development research
|January 19, 2024
概括
研究人员探索了基丁衍生物,以找到腺素A2B受体的选择性对手. XCC-NHS (MRS 1204) 成为一种强效和选择性的A2B受体对手,有效地阻断循环AMP的积累.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 氨酸受体,特别是A2B亚型,是治疗干预的目标.
- 基丁衍生物已经显示出作为腺素受体对手的潜力.
- 了解结构-活性关系 (SAR) 对于开发选择性对抗剂至关重要.
研究的目的:
- 为了研究基丁衍生物的SAR作为人类复合腺素受体的抗体.
- 为了确定特定于A2B受体亚型的选择性抗剂.
- 探索结构修改对对抗剂强度和选择性的影响.
主要方法:
- 合成和表征各种基丁衍生物在1,3,7和8位的修饰.
- 竞争结合试验使用在HEK-293表达A2B受体的细胞中的125I-ABOPX来确定K值.
- 测量循环AMP积累的功能性试验,以评估对抗剂活性对NECA刺激的反应.
主要成果:
- 用8-替代剂功能化的基丁衍生物在10100nM范围内表现出Ki值.
- XCC-NHS (MRS 1204) 是XCC的一种N-基苏胺衍生物,对A2B受体表现出高强度 (Ki=9.75nM) 和选择性 (>20倍).
- 一些强效的丁衍生物,包括XCC和XAC合物,在功能性试验中有效地对抗NECA诱导的循环AMP积累.
结论:
- 基丁的结构修改显著影响它们对氨酸A2B受体的亲和力和选择性.
- XCC-NHS (MRS 1204) 是一种有前途的化合物,用于开发选择性A2B受体抗剂.
- 这些发现为Xanthine衍生物对A2B受体对抗的SAR提供了宝贵的见解.
相关概念视频
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
880
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
880
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.0K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.0K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
813
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
813
Adrenergic Agonists: Direct-Acting Agents
1.5K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
1.5K
Adrenergic Receptors: ɑ Subtype
1.5K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.5K
Adrenergic Agonists: Indirect-Acting Agents
1.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.6K


